您当前的位置:
技术服务
发布日期:2024/9/20 16:42:00

Introduction

The paper 'Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation' by Julia C. Meier et al., published in ACS Chemical Biology (2017), explores the potential of selective inhibitors targeting bromodomains in the Bromodomain-PHD Fingers (BRPF) family to disrupt osteoclast differentiation. This process plays a crucial role in bone metabolism, and its regulation may provide therapeutic benefits for diseases like osteoporosis.

研究简介

题目:选择性靶向溴结构域-PHD手指家族的溴结构域抑制破骨细胞分化
发表期刊:ACS Chemical Biology
发表时间:2017年10月20日
作者:Julia C. Meier 等

这篇文章研究了通过选择性抑制溴结构域-PHD手指(BRPF)家族中的溴结构域来抑制破骨细胞分化的潜力。破骨细胞分化在骨代谢中起重要作用,其调控可能为骨质疏松等疾病提供治疗途径。

Key Findings

1. BRPF Bromodomains as a Target: Bromodomains recognize acetylated lysine residues on histones, influencing gene regulation. By targeting BRPF bromodomains, the study aimed to interfere with osteoclast differentiation, crucial for bone resorption.
2. Discovery of Inhibitors: The researchers identified three selective inhibitors that impaired osteoclast formation without affecting cell viability, indicating potential therapeutic applications.
3. Mechanistic Insights: The inhibitors affected gene expression related to osteoclast differentiation, providing further insight into the pathways influenced by BRPF bromodomains.
4. Therapeutic Application: The findings suggest these inhibitors could be developed for treating bone-related diseases like osteoporosis.

主要发现

1. BRPF溴结构域作为靶点:溴结构域识别组蛋白上乙酰化的赖氨酸残基,从而影响基因调控。通过靶向BRPF溴结构域,研究旨在干扰破骨细胞分化,这在骨吸收中至关重要。
2. 抑制剂的发现:研究者发现了三种选择性抑制剂,它们能在不影响细胞活力的情况下抑制破骨细胞的形成,表明其在治疗方面的潜力。
3. 机制见解:抑制剂影响与破骨细胞分化相关的基因表达,进一步阐明了BRPF溴结构域影响的通路。
4. 治疗应用:研究表明,这些抑制剂可能被开发用于治疗骨质疏松等骨相关疾病。

Related Compounds and CAS Numbers

Here are a few related compounds often studied in similar research contexts:
1. I-BET151 – CAS: 1314890-29-3
2. JQ1 – CAS: 1268524-70-4

相关产品

(S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯. 1268524-70-4
|10mg
OF-1. 919973-83-4
|10mM (in 1mL DMSO)
(+)-JQ1. 1268524-70-4
|20mg
TMP269 1314890-29-3
|100mg
(+)JQ-1 1268524-70-4
|100mg
上一篇:没有了 下一篇:Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in COVID-19